 Perioperative methotrexate vinblastine doxorubicin cisplatin M-VAC poor risk transitional cell carcinoma bladder Eastern Cooperative Oncology Group pilot study total patients advanced transitional cell carcinoma bladder underwent preoperative cycles chemotherapy methotrexate vinblastine doxorubicin cisplatin radical cystectomy postoperative cycles chemotherapy Radical cystectomy patients pathological partial response pathological complete response over-all response rate confidence median followup patients evidence recurrent disease metastatic bladder cancer Average relative dose intensity therapy Hematological toxicity moderate septic deaths complications thromboembolic events primary bladder tumor perioperative schedule results impressive findings incidence thromboembolic events worrisome